Lercanidipine Actavis

Lercanidipine, the active ingredient in Lercanidipine Actavis, is a calcium channel blocker presented as a tablet for oral use. It is prescribed to lower elevated blood pressure in adult patients diagnosed with hypertension, helping to reduce the risk of cardiovascular complications.

GNH USA supplies Lercanidipine Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium‑channel blocker used in the management of arterial hypertension. It works by relaxing vascular smooth muscle and lowering systemic vascular resistance.

- Essential hypertension: provides sustained reduction of systolic and diastolic blood pressure in patients with primary hypertension. - Isolated systolic hypertension: effectively lowers elevated systolic pressure, particularly in older adults. - Hypertension in the elderly: offers a once‑daily oral option with a favorable tolerability profile for senior patients.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth and redness, typically resolves with continued therapy. - Peripheral edema: swelling of ankles or lower legs, usually mild. - Dizziness: may occur upon standing, especially after initial dosing.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Angioedema: swelling of face, lips, tongue, or throat, potentially life‑threatening. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Allergic reactions: rash, pruritus, or anaphylaxis in rare cases.

Before initiating therapy with Lercanidipine, several safety considerations should be reviewed. - Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Hepatic function: evaluate liver enzymes in patients with known liver disease. - Aortic stenosis: use with caution in severe cases due to risk of reduced cardiac output. - Elderly patients: start at low dose and monitor for dizziness or falls. - Concomitant antihypertensives: adjust doses to prevent additive blood pressure lowering. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, influencing its efficacy and safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations and risk of hypotension. - Grapefruit juice: can elevate drug levels leading to enhanced vasodilatory effects. - Co‑administration with other potent antihypertensives: may cause excessive blood pressure reduction.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Diuretics: can amplify orthostatic hypotension. - Beta‑blockers: monitor heart rate and blood pressure for additive effects.